[go: up one dir, main page]

WO2023235633A3 - Improved salmonella vectored therapies for treatment of cancer - Google Patents

Improved salmonella vectored therapies for treatment of cancer Download PDF

Info

Publication number
WO2023235633A3
WO2023235633A3 PCT/US2023/024484 US2023024484W WO2023235633A3 WO 2023235633 A3 WO2023235633 A3 WO 2023235633A3 US 2023024484 W US2023024484 W US 2023024484W WO 2023235633 A3 WO2023235633 A3 WO 2023235633A3
Authority
WO
WIPO (PCT)
Prior art keywords
gmsc
therapies
cancer
treatment
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/024484
Other languages
French (fr)
Other versions
WO2023235633A2 (en
Inventor
Roy Curtiss
Shifeng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
University of Florida Research Foundation Inc
Original Assignee
University of Florida
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida, University of Florida Research Foundation Inc filed Critical University of Florida
Priority to EP23816835.5A priority Critical patent/EP4531880A2/en
Publication of WO2023235633A2 publication Critical patent/WO2023235633A2/en
Publication of WO2023235633A3 publication Critical patent/WO2023235633A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A genetically modified Salmonella cell (GMSC) engineered to exhibit specific targeting to cells and regulated delayed lysis in vivo, the GMSC comprising a first heterologous nucleic acid that encodes a first gene product that causes the GMSC to be selectively localized to and/or internalized by a target cell in vivo and a second heterologous nucleic acid that encodes a second gene product that facilitates killing of the target cells following internalization.
PCT/US2023/024484 2022-06-03 2023-06-05 Improved salmonella vectored therapies for treatment of cancer Ceased WO2023235633A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP23816835.5A EP4531880A2 (en) 2022-06-03 2023-06-05 Improved salmonella vectored therapies for treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263348492P 2022-06-03 2022-06-03
US63/348,492 2022-06-03

Publications (2)

Publication Number Publication Date
WO2023235633A2 WO2023235633A2 (en) 2023-12-07
WO2023235633A3 true WO2023235633A3 (en) 2024-02-08

Family

ID=89025643

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/024484 Ceased WO2023235633A2 (en) 2022-06-03 2023-06-05 Improved salmonella vectored therapies for treatment of cancer

Country Status (2)

Country Link
EP (1) EP4531880A2 (en)
WO (1) WO2023235633A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130209405A1 (en) * 2010-05-28 2013-08-15 Roy Curtiss, III Recombinant bacterium to decrease tumor growth
US10731125B2 (en) * 2012-09-13 2020-08-04 Massachusetts Institute Of Technology Programmable drug delivery profiles of tumor-targeted bacteria
WO2020172462A1 (en) * 2019-02-22 2020-08-27 Arizona Board Of Regents On Behalf Of Arizona State University Tumor-navigating, self-eradicating, trail-armed salmonella for precision cancer therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130209405A1 (en) * 2010-05-28 2013-08-15 Roy Curtiss, III Recombinant bacterium to decrease tumor growth
US10731125B2 (en) * 2012-09-13 2020-08-04 Massachusetts Institute Of Technology Programmable drug delivery profiles of tumor-targeted bacteria
WO2020172462A1 (en) * 2019-02-22 2020-08-27 Arizona Board Of Regents On Behalf Of Arizona State University Tumor-navigating, self-eradicating, trail-armed salmonella for precision cancer therapy

Also Published As

Publication number Publication date
WO2023235633A2 (en) 2023-12-07
EP4531880A2 (en) 2025-04-09

Similar Documents

Publication Publication Date Title
WO2020163365A3 (en) Combination gene targets for improved immunotherapy
WO2020014543A3 (en) Engineered immunostimulatory bacterial strains and uses thereof
Altaner Prodrug cancer gene therapy
Minton Clostridia in cancer therapy
Wei et al. Bacterial targeted tumour therapy-dawn of a new era
PH12022550693A1 (en) Multi-specific binding proteins for cancer treatment
WO2020181168A8 (en) Non-active lipid nanoparticles with non-viral, capsid free dna
MY176922A (en) Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis
WO2013074059A3 (en) Cytosine deaminase modulators for enhancement of dna transfection
Yang et al. Progress in gene therapy using oncolytic vaccinia virus as vectors
WO2023004367A3 (en) Engineered targeting compositions for endothelial cells of the central nervous system vasculature and methods of use thereof
MX2023012747A (en) Compositions and methods for in vivo nuclease-mediated gene targeting for the treatment of genetic disorders.
MX2023009113A (en) Immunostimulatory compounds and conjugates.
Zou et al. Augmentation of epithelial resistance to invading bacteria by using mRNA transfections
Glinka Eukaryotic expression vectors bearing genes encoding cytotoxic proteins for cancer gene therapy
SG10201907746TA (en) Methods of treating cancer harboring hemizygous loss of tp53
MX2022008485A (en) A method of engineering natural killer cells to target cd70-positive tumors.
MY195280A (en) Nucleic Acid Systems That Enable Bacteria to Specifically Target Solid Tumors Via Glucose-Dependent Viability
MX2022005670A (en) Compositions and methods for high-efficiency recombination of rna molecules.
WO2023235633A3 (en) Improved salmonella vectored therapies for treatment of cancer
Tripodi et al. Evaluation of the antiproliferative effect of Bifidobacterium longum BB-536 in solid tumor cell lines, co-cultured with murine splenocytes
WO2019164872A3 (en) Composition and method for targeting natural killer cells in immunotherapy to overcome tumor suppression with manganese dioxide nanoparticles
WO2024030970A3 (en) Genetic editing of target genes to enhance natural killer cell function
WO2021141977A8 (en) Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
WO2020163408A3 (en) Fusogenic lipid nanoparticles for the target cell-specific production of rapamycin inducible therapeutic proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23816835

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2023816835

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023816835

Country of ref document: EP

Effective date: 20250103

WWP Wipo information: published in national office

Ref document number: 2023816835

Country of ref document: EP